Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible. Dieser Artikel ist nicht verfügbar.Moonshot: Inside Pfizer's Nine-Month Race to Make the Impossible Possible

Wall Street Journal Bestseller

2022 Genesis Prize Laureate

Axiom Award Bronze Medalist for Business Intelligence / Innovation

The exclusive, first-hand, behind-the-scenes story of how Pfizer raced to create the first Covid-19 vaccine, told by Pfizer’s Chairman and CEO Dr. Albert Bourla.

A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made “the impossible possible”―creating, testing, and manufacturing a safe and effective Covid-19 vaccine that previously would have taken years to develop. 

Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer, under the enormous strains of the global pandemic, overcame a series of crises that were compounded by social and political unrest, and reveals the doubts, decisions, obstacles, and failures they encountered. As Dr. Bourla makes clear, Pfizer’s success wasn’t due to luck; it was because of preparation driven by four simple values―Courage, Excellence, Equity, and Joy.

Moonshot is a story of leadership under the most unprecedented circumstances―how Dr. Bourla, a Greek immigrant, a child of Holocaust survivors, and a veterinarian, became the head of one of the world’s largest corporations and initiated a dramatic transformation of the organization just before a global health crisis would serve to test the organization, its scientists, and its leader, like never before. Moonshot describes best practices that can be used to address the multiple, unprecedented challenges our world faces, reveals Pfizer’s implementation of scientific breakthroughs at a record-breaking pace, and offers leadership lessons that can help anyone successfully manage their own seemingly unsolvable problems. As Dr. Bourla explains, “I am sharing the story of our moonshot―the challenges we faced, the lessons we learned, and the core values that allowed us to make it happen―in hopes that it might inspire and inform your own moonshot, whatever that may be.”

This story of leadership under pressure reveals:

• Leadership Lessons: How four simple values—Courage, Excellence, Equity, and Joy—drove high-stakes decisions and prepared an organization to make “the impossible possible” during a global crisis.
• Purpose-Driven Culture: The inside story of how a Greek immigrant and child of Holocaust survivors transformed one of the world’s largest corporations into an agile, science-focused innovator just in time.
• High-Stakes Innovation: A behind-the-scenes account of the counterintuitive, high-risk decision to pursue untested mRNA technology and develop a manufacturing process for it from scratch.
• Supply Chain Logistics: The story of the “second miracle”—inventing freezer farms, thermal shippers with GPS trackers, and a global distribution network to deliver a temperature-sensitive vaccine at unprecedented scale.

Dr. Albert Bourla became the CEO of Pfizer in January 2019. He began his career at the company in 1993, in the Animal Health Division as technical director of Greece, and has served in numerous executive positions within the company, including COO, Group President of Pfizer Innovative Health, and Group President of Pfizer's Global Vaccines, Oncology, and Consumer Healthcare business. He is a doctor of veterinary medicine and holds a PhD in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. In addition to his responsibilities at Pfizer, Dr. Bourla is on the executive committee of The Partnership for New York City; a director on multiple boards, including Pfizer Inc., PhRMA, and Catalyst; a Trustee of the United States Council for International Business; and a member of the Business Roundtable and the Business Council. In 2020, Dr. Bourla was named America's top CEO in the pharmaceuticals sector by Institutional Investor magazine.